# Nadine Carbuccia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4100878/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 55<br>papers | 3,200<br>citations | 257357<br>24<br>h-index | 197736<br>49<br>g-index |
| 56<br>all docs | 56<br>docs citations | 56<br>times ranked | 4678<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Mutations of polycombâ€associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2009, 145, 788-800. | 1.2 | 537 |
| 2 | Genomic characterization of metastatic breast cancers. Nature, 2019, 569, 560-564. | 13.7 | 448 |
| 3 | Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia, 2009, 23, 2183-2186. | 3.3 | 301 |
| 4 | Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218. | 0.6 | 220 |
| 5 | ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. British Journal of Haematology, 2010, 151, 365-375. | 1.2 | 199 |
| 6 | Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401. | 1.1 | 140 |
| 7 | Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes and Cancer, 2012, 51, 743-755. | 1.5 | 139 |
| 8 | Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene, 2006, 25, 1560-1570. | 2.6 | 132 |
| 9 | Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia, 2010, 24, 469-473. | 3.3 | 106 |
| 10 | Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, 2016, 7, 27208-27219. | 0.8 | 69 |
| 11 | Acute myeloid leukemia with myelodysplasiaâ€related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. American Journal of Hematology, 2012, 87, 659-662. | 2.0 | 67 |
| 12 | Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology, 1995, 27, 235-241. | 1.6 | 57 |
| 13 | Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, 2014, 9, e81843. | 1.1 | 53 |
| 14 | Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia, 2009, 23, 85-94. | 3.3 | 49 |
| 15 | Alteration of cohesin genes in myeloid diseases. American Journal of Hematology, 2010, 85, 717-719. | 2.0 | 46 |
| 16 | Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene, 2004, 23, 9381-9391. | 2.6 | 44 |
| 17 | Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica, 2017, 102, e11-e14. | 1.7 | 42 |
| 18 | Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e33-e33. | 2.8 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The Expression of FMS, KIT and FLT3 in Hematopoietic Malignancies. Leukemia and Lymphoma, 1994, 13, 223-227. | 0.6 | 35 |
| 20 | A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leukemia Research, 2010, 34, 254-257. | 0.4 | 35 |
| 21 | Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia, 2016, 30, 966-970. | 3.3 | 31 |
| 22 | Simple variant t(8;21) acute myeloid leukemias harbor insertions of theAML1 orETO genes. , 1999, 24, 165-171. | | 28 |
| 23 | Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genetics and Cytogenetics, 2007, 176, 80-88. | 1.0 | 26 |
| 24 | Concomitant germâ€line <scp>RUNX</scp>1 and acquired <scp>ASXL</scp>1 mutations in a Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2013, 91, 277-279. | 1.1 | 25 |
| 25 | A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, 2019, 11, 665. | 1.7 | 25 |
| 26 | Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. British Journal of Haematology, 2004, 125, 601-604. | 1.2 | 24 |
| 27 | Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder. Cancer Genetics and Cytogenetics, 2007, 173, 154-158. | 1.0 | 24 |
| 28 | Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110â€“FGFR1 fusion: Report of a new case and review of the literature. Leukemia Research, 2008, 32, 1304-1308. | 0.4 | 24 |
| 29 | Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87. | 3.6 | 24 |
| 30 | NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519. | 2.1 | 23 |
| 31 | Unbalanced translocation t(5;17) in an atypical acute promyelocytic leukemia. Genes Chromosomes and Cancer, 1995, 14, 307-312. | 1.5 | 22 |
| 32 | Monensin action on the Golgi complex in perfused rat liver: Evidence against bile salt vesicular transport. Gastroenterology, 1992, 102, 2024-2032. | 0.6 | 21 |
| 33 | Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5, e292-e292. | 2.8 | 21 |
| 34 | Search for Rearrangements and/or Allelic Loss of the fas/APO-1 Gene in 101 Human Lymphoma. American Journal of Clinical Pathology, 1995, 104, 424-430. | 0.4 | 17 |
| 35 | Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes and Cancer, 2020, 59, 30-39. | 1.5 | 17 |
| 36 | Overcoming Resistance to Antiâ€“Nectin-4 Antibody-Drug Conjugate. Molecular Cancer Therapeutics, 2022, 21, 1227-1235. | 1.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441. | 0.8 | 11 |
| 38 | Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification. Blood Cancer Journal, 2017, 7, e594-e594. | 2.8 | 10 |
| 39 | Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 2022, 41, 125-137. | 2.6 | 10 |
| 40 | Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters, 2010, 1, 883-884. | 0.8 | 7 |
| 41 | Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia, 2010, 24, 1539-1541. | 3.3 | 7 |
| 42 | TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. European Journal of Cancer, 2021, 159, 205-214. | 1.3 | 7 |
| 43 | Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genomeâ€wide clonal evolution. Histopathology, 2019, 74, 654-662. | 1.6 | 6 |
| 44 | High Response to Cetuximab in a Patient With EGFR-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2019, 3, 1-8. | 1.5 | 5 |
| 45 | Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1289-1293. | 0.6 | 4 |
| 46 | Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. Molecular Oncology, 2022, 16, 2057-2070. | 2.1 | 4 |
| 47 | Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO Precision Oncology, 2018, 2, 1-8. | 1.5 | 2 |
| 48 | Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. Journal of Personalized Medicine, 2022, 12, 655. | 1.1 | 2 |
| 49 | RETROSPHER. ERBB2 amplification detection in the plasma at diagnosis for early high-risk HER2-positive breast cancer. Annals of Oncology, 2018, 29, vi1. | 0.6 | 1 |
| 50 | Epigenetically centered evolution in an example of myeloid malignancy. American Journal of Hematology, 2016, 91, E361-2. | 2.0 | 0 |
| 51 | Circulating tumour DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma, the CIDOC study. Annals of Oncology, 2018, 29, vi3. | 0.6 | 0 |
| 52 | Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B. JCO Precision Oncology, 2019, 3, 1-9. | 1.5 | 0 |
| 53 | Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients. Blood, 2018, 132, 1401-1401. | 0.6 | 0 |
| 54 | Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. Cancers, 2022, 14, 2275. | 1.7 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | 3115 â€“ INTEGRATIVE MULTI-OMICS ANALYSIS FOR UNDERSTANDING ACUTE PROMYELOCYTIC LEUKEMIA RESISTANCE: EZH2 ON THE ROAD. Experimental Hematology, 2021, 100, S98. | 0.2 | 0 |